Equities research analysts at Needham & Company LLC initiated coverage on shares of Legend Biotech (NASDAQ:PCVX) in a research note issued on Tuesday, The Fly reports. The firm set a “buy” rating on the stock.
Separately, Cantor Fitzgerald started coverage on shares of Legend Biotech in a report on Tuesday. They set an “overweight” rating for the company.
Shares of PCVX opened at $29.99 on Tuesday. Legend Biotech has a 1 year low of $17.80 and a 1 year high of $36.50.
Legend Biotech Company Profile
Vaxcyte, Inc a biopharmaceutical company, develops vaccines for infectious diseases. It offers conjugate, pneumococcal conjugate, and complex antigen-based vaccines. The company has a license to Sutro Biopharma's Xpress CF platforms for cell free protein synthesis and site-specific conjugation. Vaxcyte, Inc was formerly known as SutroVax, Inc and changed its name to Vaxcyte, Inc in May, 2020.
Featured Story: What sectors are represented in the Hang Seng index?
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.